The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy as second-line is unknown. The aim of the present report was to describe outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment.
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients / Buti, Sebastiano; Trentini, Francesca; Sepe, Pierangela; Claps, Melanie; Isella, Luca; Verzoni, Elena; Procopio, Giuseppe. - In: TUMORI. - ISSN 0300-8916. - (2022), p. 3008916221141483. [10.1177/03008916221141483]
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
Buti, Sebastiano;Trentini, Francesca;Isella, Luca;
2022-01-01
Abstract
The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy as second-line is unknown. The aim of the present report was to describe outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
